Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05018650 · ClinicalTrials.gov registry record · NA
A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)
A NA study, sponsored by Route 92 Medical.
- Completed
- Registry status
- NA
- Development phase
- 250
- Enrollment target
NCT05018650 is a NA study that has completed, run by Route 92 Medical. The registered enrollment target is 250 participants.
The verdict
NCT05018650, a NA study, has completed, sponsored by Route 92 Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
Study Summary
The SUMMIT MAX study is a prospective, randomized, controlled, interventional clinical trial to evaluate the safety and effectiveness of the Route 92 Medical MonoPoint® Reperfusion System with the Hi Point 88 and HiPoint 70 Reperfusion Catheters for aspiration thrombectomy in acute ischemic stroke patients.
Interventions
- DEVICE Route 92 Medical Reperfusion System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2024-05-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05018650
The ClinicalTrials.gov registry entry for NCT05018650 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Route 92 Medical, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Route 92 Medical Reperfusion System is the first listed.
NCT05018650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05018650 about?
NCT05018650 is a clinical study titled "A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)". The SUMMIT MAX study is a prospective, randomized, controlled, interventional clinical trial to evaluate the safety and effectiveness of the Route 92 Medical MonoPoint® Reperfusion System with the Hi Point 88 and HiPoint 70 Reperfusion Catheters for aspiration thrombectomy in acute ischemic stroke p...
What is the current status of trial NCT05018650?
This trial is currently completed. It is a NA study. The enrollment target is 250 participants. The study started on 2021-12-21. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT05018650?
The interventions under investigation include: Route 92 Medical Reperfusion System (DEVICE).
Who is sponsoring clinical trial NCT05018650?
This trial is sponsored by Route 92 Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.